Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 15.48B | -66.5x | 0.36 | SEK 174.90 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioInvent International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.64B | -6.4x | 0.23 | SEK 40.25 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Egetis Therapeutics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.37B | -6x | -0.33 | SEK 6.59 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hansa Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.07B | -2.8x | -0.1 | SEK 30.40 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Devyser Diagnostics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.01B | -30.8x | 1.25 | SEK 120.50 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
Vicore Pharma Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.82B | -4.4x | -0.22 | SEK 7.72 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Diamyd Medical | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.58B | -9.5x | 1.27 | SEK 15.24 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cereno Scientific | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.55B | -20.6x | 0.41 | SEK 5.50 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
XSpray Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.50B | -5.6x | 1.21 | SEK 44.50 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nanoform Finland Plc | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.30B | -4.9x | 1.7 | SEK 14.52 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellego Technologies AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.15B | 13.8x | 0.16 | SEK 42.70 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nykode Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 916.33M | -1.9x | SEK 13.98 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Saniona AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 755.23M | -7.7x | -0.35 | SEK 6.74 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9.8% Downside | Upgrade to Pro+ | |
Hamlet Pharma AB | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 587.17M | -14.4x | 0.74 | SEK 3.50 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Promimic AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 492.55M | -48.5x | 2.66 | SEK 26.10 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SynAct Pharma AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 450.96M | -2.7x | -0.14 | SEK 10.62 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mendus AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 438.03M | -2.9x | -0.06 | SEK 8.70 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Initiator Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 402.14M | -23.7x | -0.39 | SEK 7.15 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Peptonic Medical | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 345.56M | -0.4x | -0.01 | SEK 0.004 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oncopeptides | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 333.97M | -0.8x | -0.04 | SEK 1.57 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cantargia AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 330.64M | -1.7x | -0.04 | SEK 1.80 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Curasight AS | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 326.79M | -7.2x | 0.51 | SEK 16.21 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alzinova | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 317.43M | -10.6x | -0.75 | SEK 3.58 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascelia Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 307.54M | -2x | -0.07 | SEK 3.45 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medivir B | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 293.88M | -0.09 | SEK 2.61 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Xbrane Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 260.01M | -0.4x | -0.01 | SEK 0.17 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Guard Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 228.68M | -2.3x | -0.07 | SEK 18.60 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abliva AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 225.66M | -1.9x | -0.19 | SEK 0.14 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Annexin Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 223.32M | -2.9x | -0.11 | SEK 0.42 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SenzaGen | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 209.48M | -10.2x | -0.44 | SEK 7.10 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |